Single Payer Neg - CNDI 2023
Single Payer Neg - CNDI 2023.docx
Indexed text preview
Single Payer Neg AT: Health Care Adv AT: US Public Health Weak Enrollment in healthcare programs at an all-time high Lagasse FEB ‘23 Jeff Lagasse, Associate Editor Healthcare Finance, “Medicare Advantage still growing, but the growth is slowing”, Healthcare Finance, July 12, 2023, https://www.healthcarefinancenews.com/news/medicare-advantage-still-growing-growth-slowing LE Medicare Advantage continues to grow, hitting record enrollment this year and increasing overall program participation by 5.5%, while adding 1.5 million beneficiaries. But according to data from Chartis, the pace of this growth is slowing. In 2020, 2021 and 2022, Medicare Advantage enrollment grew by 1.9 million, 2.2 million and 2.3 million beneficiaries, respectively. This year, Medicare Advantage enrollment grew by just 1.5 million. While that's still significant growth, it does show evidence of a deceleration. At the same time, original Medicare continues to decline, losing 339,000 enrollees this year – a significant but smaller loss than previous years. Special Needs Plans (SNP) enrollment accounted for two-thirds of total market growth. SNP enrollment is up 20% from 2022, driven by considerable D-SNP enrollment gains. A total of 29.5 million beneficiaries are now enrolled in a Medicare Advantage plan, according to Chartis. This year, for-profit insurers account for 72.6% of all Medicare Advantage enrollment, up from 71.8% the year prior and 67.9% in 2019. This marks a 4.7 percentage point share increase over that period, and annual growth of 10.1%, found Chartis. Meanwhile, nonprofit plans continue to see share declines, although their enrollment is still growing. For the first time in many years, nonprofit Blues plans notched a market share gain of 0.2 percentage point. While modest, this increase sits in stark contrast to remaining nonprofit plans, which saw a 0.8 percentage point share decline, continuing prior years' losses. Conversely, for-profit United accounted for 55% of all new enrollment. In prior years, this hovered in the 30% to 40% range. Humana accounted for 23% of all new enrollment, meaning the two health plans combined represent four in five new enrollees nationally. Start-up plans continue to grow, although their advances have slowed. Overall, start-up plans participating in Medicare Advantage notched 7% growth this year. This growth exceeds the market average, but pales in comparison to their prior years' annual membership growth of +25%. Their current share of the market now sits at 1.7%. Three states and Washington D.C. saw enrollment declines. This is the first time in recent history that Chartis has seen enrollment declines in key states. Meanwhile, 15 states now boast Medicare Advantage enrollment rates at or exceeding 50%. Plan options have reached an all-time high, but health plan competition is limited, data showed. Plan options for consumers have been growing more than 11% per year. This year, the average member had access to 43 different plan options, up from 24 in 2019 – a growth of nearly 80%. Despite this, at the county level competition in the market continues to deteriorate. Nearly 85% of counties are considered "highly concentrated." Meanwhile, quality performance correlates to enrollment performance. Seventy-three percent of Medicare Advantage beneficiaries are enrolled in health plans receiving four-plus stars this year, down from 89% the year prior. Health plans that saw their quality rating increase realized 9.6% enrollment gains, despite only 3.5% growth for health plans that saw their ratings decline this year. On February 1, the Centers for Medicare and Medicaid Services released the 2024 Advance Notice for the Medicare Advantage and Part D Prescription Drug Programs, in which CMS said MA plans are expected to receive a 1.03% increase in revenue. However, three changes in the rate notice would, on average, cut MA rates in 2024 by 2.27%, AHIP president and CEO Matt Eyles said in a statement last week. These three changes include: a 3.12% reduction, due to the MA risk model that accounts for the health status and demographic characteristics of enrollees; 1.24% lower quality bonus payments under the Medicare Star Ratings program; and increase benchmarks used to set maximum payment rates on average by 2.09%, which is less than half the growth rate in 2023 (4.88%) and well below the projected growth in per-enrollee Medicare costs (5%). Eyles was responding to a Department of Health and Human Services statement called "Fact v. Fiction: Biden-Harris Administration is Strengthening Medicare; Private Industry Must Share Obligation to Deliver Quality Health Care for America's Seniors." AT: US Unprepared The US is already responding to the risk of bioterrorism – smallpox vaccines prove Keown 18 [Alex Keown, Chicago-based professional reporter and editor, “With Looming Bioterrorism Threats, FDA Approves First Smallpox Therapeutic,” BioSpace, 7-16-18, https://www.biospace.com/article/with-looming-bioterrorism-threats-fda-approves-first-smallpox-therapeutic/] Shares of SIGA Technologies soared more than 11 percent late Friday after the company announced that its smallpox treatment Tpoxx was approved by the U.S. Food and Drug Administration (FDA). This is the first approved treatment for the disease that at one time was believed to have been eradicated, but due to the threat of bioterrorism has become an increased concern for the world. Because of the bioterrorism threats, the government pushed for the development of medical countermeasures to the dreaded disease. While vaccines are important, the government believed there should be a therapeutic available to reduce the chance of mass deaths should a bioweapon be used. After the prevalence of the smallpox vaccine, the last outbreak of the deadly disease that occurred in the United States was in 1949. The disease had been declared eradicated by the World Health Organization in 1980 The FDA greenlit Tpoxx based on data from six different trials involving animals. Four trials involved primates and two involved rabbits. The primates were infected with monkeypox virus and the rabbits were infected with rabbitpox. The trials demonstrated that Tpoxx “significantly reduced both mortality and viral load” in the animals. The results of these studies were published in the July 5, 2018 issue of the New England Journal of Medicine. Siga said that the FDA’s approval came two months after the agency’s Antimicrobial Drugs Advisory Committee voted unanimously, 17 to 0, in support of the medication. Siga used a Priority Review Voucher in order to gain an accelerated review of its medicine. The accelerated review marked the first time that was used under the Material Threat Countermeasure PRV program enacted by the 2016 21st Century Cures Act, Siga said in its announcement. Tpoxx (tecovirimat) was approved in order to mitigate the impact of a potential outbreak, the company said. “The FDA approval of TPOXX achieves an important objective for both SIGA and our lead partner in the U.S. Government, the Biomedical Advanced Research and Development Authority (BARDA). The approval validates this novel smallpox therapy as an important medical countermeasure in response to a potential smallpox outbreak,” Siga Chief Executive Officer Phil Gomez said in a statement. Siga’s Tpoxx was developed with support from the Biomedical Advanced Research and Development Authority (BARDA). With the FDA approval, Siga said it will ask BARDA to exercise an option for a $50 million payment to the company based on this extended shelf-life determination. With the approval, SIGA is entitled to a $41 million holdback payment under the existing contract with BARDA, provided that BARDA confirms that there is no difference between the approved product and the courses of TPOXX that have already been delivered to the Strategic National Stockpile (SNS), the company said in its announcement. Tpoxx will be available for use through the U.S. government’s Strategic National Stockpile. There have been about two million doses of the treatment delivered to the stockpile, the company said. Siga said some members of the Antimicrobial Drugs Advisory Committee suggested that there could be additional uses for Tpoxx, including prophylactic use in individuals exposed to smallpox and other orthopoxviruses, such as monkeypox, which can jump that species barrier. Siga said it will examine these potential markets and the feasibility of expanding the TPOXX label to include these indications. Turn - Private Equity - Uq Private Equity investment is increasing, and it helps create more effective healthcare Whoriskey 7-10 (Peter Whoriskey has been a staff writer for The Washington Post since 2001, covering an array of subjects, including financial inequality, the pharmaceutical industry, hospice care, organic food fraud and private equity, “Private equity investors raising U.S. medical prices, study says,” The Washington Post, July 10, 2023, https://www.washingtonpost.com/business/2023/07/10/private-equity-raising-prices-doctors-practices-private-equity-doctors/) Private equity firms are rapidly acquiring physician practices, gaining significant market share in many cities and boosting medical prices in an array of specialties, according to an academic study released Monday. The study focused on private equity “roll ups” of physician practices, in which investors buy up several doctor groups in a city, consolidating a significant share of the market which they can use to raise prices. The report found that “PE acquisitions are associated with price increases in 8 of 10 specialties, and that these price increases are particularly high in [metropolitan areas] where a single PE firm controls more than 30% of the market.” For example, prices for gastroenterologists jumped 14 percent, for oncologists they rose 16 percent and for ophthalmologists it was 9 percent, according to the research, a project from the University of California at Berkeley, the Washington Center for Equitable Growth and the American Antitrust Institute. Price hikes were higher when a private equity-owned practice controlled a large share of the market. The study found that the number of metropolitan areas in which a private equity firm served half or more of a market rose from a handful in 2012 to 50 in 2021. A recent Washington Post story chronicled the price hikes that followed a private equity venture into anesthesia. The study authors urged federal regulators to more closely examine the effects of private equity investments in medical groups. “The vast majority of [private equity] acquisitions in this report took place without federal antitrust scrutiny and with limited state antitrust scrutiny,” the authors wrote. In recent months, antitrust enforcers at the U.S. Department of Justice and the Federal Trade Commission have talked of applying more scrutiny to private equity acquisitions of physician practices. “To the extent that private equity transactions and conduct are focused on short-term gains and aggressive cost-cutting in the health care space, they can lead to disastrous patient outcomes,” Deputy Assistant Attorney General Andrew Forman, said in a speech last year. Private equity firms say that their investments in physician practices have created more efficient systems of billing and medical records, enabling doctors to focus on patients. “Private equity investment is helping improve patient care and ensuring that residents have high quality facilities in their local communities,” Drew Maloney, president of the American Investment Council, a private equity industry group, said in a statement for this story. “By partnering with private equity firms, physicians have more time to focus on caring for patients and benefit from experienced management teams, better technology, and stronger networks.” The economics of practicing medicine have undergone a profound change in recent decades, with many doctors shifting from small practices that they owned to working for larger practices that are owned by corporations, hospitals, insurers and, more recently, private equity firms. The study reported that private equity firms have shown increasing interest in acquiring physician practices, with the number of deals studied rising from 75 in 2012 to 484 in 2021. The largest number of deals occurred in dermatology, ophthalmology, gastroenterology and primary care. The other specialties considered in the study were cardiology, oncology, obstetrics and gynecology, orthopedics, urology, and radiology. Private equity in medical treatment now Abelson and Sanger-Katz 7-10 [Reed Abelson and Margot Sanger-Katz, Reed Abelson and Margot Sanger-Katz have both reported on the changing economics of medicine for more than a decade, “Who Employs Your Doctor? Increasingly, a Private Equity Firm,” The New York Times, 7-10-23, https://www.nytimes.com/2023/07/10/upshot/private-equity-doctors-offices.html] [ST] In recent years, private equity firms have been gobbling up physician practices to form powerful medical groups across the country, according to a new report released Monday. In more than a quarter of local markets — in places like Tucson, Ariz.; Columbus, Ohio; and Providence, R.I. — a single private equity firm owned more than 30 percent of practices in a given specialty in 2021. In 13 percent of the markets, the firms owned groups employing more than half the local specialists. The medical groups were associated with higher prices in their respective markets, particularly when they controlled a dominant share, according to a paper by researchers at the Petris Center at the University of California, Berkeley, and the Washington Center for Equitable Growth, a progressive think tank in Washington, D.C. When a firm controlled more than 30 percent of the market, the cost of care in three specialties — gastroenterology, dermatology, and obstetrics and gynecology — increased by double digits. The paper, published by the American Antitrust Institute, documented substantial private equity purchases across multiple medical specialties over the last decade. Urology, ophthalmology, cardiology, oncology, radiology and orthopedics have also been major targets for such deals. “It’s shocking when you look at it,” said Laura Alexander, director of markets and competition policy for the Washington Center, who said private equity firms dominated only a handful of markets a decade ago. By looking at individual markets, the researchers were able to document the local impact. “National rates mask this much more acute problem in local markets,” she said. The higher prices paid by private insurers contribute to high insurance premiums, and may increase out-of-pocket costs for patients. Private equity firms, which pool funds from institutional investors and individuals to form investment funds, tend to purchase companies using debt, with an eye to reselling them in a few years. The industry has turned to health care fairly recently, but it has begun purchasing doctors’ practices at a steady clip, combining smaller practices to form larger companies. When a private equity arm of a Canadian pension fund, OMERS Private Equity, bought Gastro Health, a large gastroenterology medical group, in 2021, it proceeded to acquire nearly a dozen smaller practices, according to the researchers, who say the group is now dominant in markets including the Miami area. The company now operates in seven states, employing over 390 doctors. The researchers saw similar patterns in other markets, where a firm would buy one large practice, then increase its market share by adding nearby smaller practices in the same medical specialty. Historically, doctors’ practices have been relatively small, and owned by doctors themselves. But that model has been rapidly declining as the business of medicine has become more complex and the insurance companies that negotiate with doctors over prices have become bigger. Nearly 70 percent of all doctors were employed by either a hospital or a corporation in 2021, according to a recent analysis from the Physicians Advocacy Institute. “We’re seeing a fundamental change in how medicine is being practiced in the U.S.,” said Richard Scheffler, a professor of health economics and public policy at Berkeley and director of the Petris Center. Hospitals and insurance companies have also bought out many independent physicians’ practices. Optum, an arm of the publicly traded UnitedHealth Group, which also owns one of the nation’s largest insurers, employs roughly 70,000 physicians. Studies have shown that these types of concentrated ownership of doctors in a given market are also associated with higher prices. Private equity is often viewed by physicians as an attractive alternative to having their practice bought by a hospital. In part, the doctors are “getting more scale and gaining efficiencies,” including help with office administration and technology, said Lisa Walkush, a national managing principal for the professional services firm Grant Thornton. “It can be a really good thing, but the private equity firms have to keep their promises and be held accountable,” she said. Michael Kroin, the founder and chief executive of Physician Growth Partners, a Chicago firm that advises independent practices, said the private equity firms “provide scale to allow independent practice groups to survive and maintain their autonomy.” If they could, given their rising costs and how squeezed they feel by insurers, “every independent group would want to increase its fees,” he said. The private equity industry has begun to attract particular scrutiny from researchers and policymakers. Lawmakers in the House are considering legislation to require more reporting when the firms buy health care companies. Currently, the acquisitions can be difficult to track. The authors of the new paper relied on data on deals from a company called PitchBook, which they then matched with doctors in a health care claims database to measure payments from private health insurers. The researchers couldn’t be sure whether the payment increases they measured happened because doctors were performing more complex procedures or just negotiating higher prices, but they suspected the prices explained most of the effect. Previous studies of private equity-acquired hospitals and physician practices from Zirui Song, an associate professor of health policy and medicine at Harvard Medical School, have also documented increasing revenue associated with the purchases. In an interview, Dr. Song said he expected the industry would continue to buy doctors’ practices in the coming years. “We still have a lot of small physician-owned specialty practices,” he said. “That’s an opportunity for consolidation. It’s an easy opportunity.” Critics of the industry, including Professor Scheffler, have also raised concerns about the medical care delivered by private equity-owned health care companies, arguing that the industry’s emphasis on profits could cause patient harm. Research on private equity ownership of nursing homes has shown evidence of lower staffing levels and higher rates of prescriptions for antipsychotic medicines. But little rigorous research has been published on patient care in the office-based medical specialties that the new paper focuses on. How the change in ownership and independence affects doctors and how they treat patients “has been very severely understudied,” said Barak Richman, a professor of law and business administration at Duke University, who reviewed the paper. But he said there is evidence that these firms are skilled at exploiting loopholes in existing regulations to maximize their profits. “Private equity is like the system on steroids,” said Sherry Glied, the dean of the Wagner School of Public Service at New York University. “Every time there’s an opportunity for making money, P.E. is going to move faster than everyone else. And consolida
Preview shortened. Download the file for the full document.